IMUX

IMMUNIC, INC. IMUX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-34.10M

Quarter to Jun 30

Free cash flow

$-31.25M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$130.65M total
abrdn plc
$12.67M-90.0%
BVF INC/IL
$11.76M-90.0%
MILLENNIUM MANAGEMENT LLC
$11.38M-80.4%
Avidity Partners Management LP
$10.30M0.0%
BRAIDWELL LP
$9.91MNew
Laurion Capital Management LP
$9.38M-84.3%
VANGUARD CAPITAL MANAGEMENT LLC
$8.78M-88.9%
Jones Hill Capital LP
$8.30MNew
Woodline Partners LP
$7.25M-51.2%
Soleus Capital Management, L.P.
$6.92M-90.0%
Propel Bio Management, LLC
$5.00M-86.1%
Nantahala Capital Management, LLC
$3.85M-90.0%
UBS Group AG
$2.70M-66.4%
GEODE CAPITAL MANAGEMENT, LLC
$2.62M-88.8%
683 Capital Management, LLC
$2.26M-94.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$2.15M-90.0%
BlackRock, Inc.
$2.04M-86.2%
MARSHALL WACE, LLP
$1.61M-89.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.40M-91.2%
JANE STREET GROUP, LLC
$1.38M-86.4%
LEUCADIA NATIONAL CORP
$1.30MNew
VANGUARD FIDUCIARY TRUST CO
$1.26M-88.9%
Ikarian Capital, LLC
$1.04M-90.0%
STATE STREET CORP
$941.6K-89.2%
Quadrature Capital Ltd
$580.8K+27.5%
See all 56 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IMUX

Earnings Per Share

13fpro.ai/company/IMUX

Loading ratio trend…

IMUX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About IMMUNIC, INC. (IMUX): stock profile, AI score and financials

IMMUNIC, INC. (IMUX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. IMUX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), IMMUNIC, INC. reports net income of $-34.1M, free cash flow of $-31.2M. Top institutional holders of IMUX by reported 13-F value include abrdn plc, BVF, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. IMUX trades on the Nasdaq exchange and files with the SEC under CIK 1280776. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMUX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUNIC, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1280776 →